CXCL12 alone is enough to Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts

Area of Science:

• Oncology
• Cell Biology
• Cancer Research

Background:

• Cancer-associated fibroblasts (CAFs) are key regulators of the tumor microenvironment (TME) and cancer progression.
• The mechanisms driving CAF activation and their role in reprogramming normal fibroblasts remain incompletely understood.
• Understanding CAF activation is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To investigate how CAFs induce normal fibroblasts (NFs) to become CAFs in lung cancer.
• To elucidate the role of p53 mutations and the CXCL12/STAT3 signaling axis in this conversion process.
• To evaluate the therapeutic potential of targeting the CXCL12/STAT3 axis in lung cancer.

Main Methods:

• In vitro co-culture systems to assess fibroblast reprogramming.
• Analysis of CAF markers (α-SMA, Vimentin) and fibroblast proliferation/migration.
• In vivo xenograft models to evaluate tumor growth and metastasis.
• Investigation of the CXCL12/STAT3 signaling pathway and its inhibition.

Main Results:

• CAFs induced NFs to acquire CAF properties (termed CEFs), enhancing proliferation, migration, and lung cancer cell promotion.
• CEFs accelerated tumor growth and induced lung metastasis in vivo.
• CXCL12 was identified as a critical factor in NFs-to-CEFs conversion, correlating with CAF markers.
• CXCL12 reprogrammed NFs to CAFs via the STAT3 pathway; inhibition of this axis reduced conversion and hindered lung cancer progression.

Conclusions:

• CAFs promote the conversion of NFs into CAF-like cells through the CXCL12/STAT3 axis in lung cancer.
• This reprogramming enhances tumor growth and metastasis.
• Targeting the CXCL12/STAT3 axis presents a promising therapeutic strategy for lung cancer and other CXCL12-dependent malignancies.